Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

2012526 citationsJournal Article

Authors

Giancarlo Agnelli · University of Perugia

Daniel J. George · Duke Medical Center

Ajay K. Kakkar · University College London

Winfield S. Fisher · McGill University Health Centre

Michael R. Lassen · Copenhagen University Hospital

Patrick Mismetti · Université Jean Monnet

Patrick Mouret

Abstract

Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy for cancer, with no apparent increase in major bleeding. (Funded by Sanofi; ClinicalTrials.gov number, NCT00694382.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Central Venous Catheters and Hemodialysis Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 7, pp. 601-609

DOI: 10.1056/nejmoa1108898

Field-Weighted Citation Impact: 33.78